Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Maubec

Showing results (51-60 of 53) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 53 results.
ESMO Open|November 3, 2023
Long term activity of vemurafenib in cancers with BRAF mutations: the ACSE basket study for advanced cancers other than BRAF<sup>V600</sup>-mutated melanomaJ Y Blay, C Cropet, S Mansard, et al.
The British Journal of Dermatology|November 1, 2020
Epidemiological changes in cutaneous lymphomas: an analysis of 8593 patients from the French Cutaneous Lymphoma RegistryG Dobos, A de Masson, C Ram-Wolff, et al.
Annales De Dermatologie Et De Venereologie|February 7, 2024
The combination of ipilimumab and nivolumab is still not reimbursed for BRAF-mutated melanoma patients in France: An unacceptable medical situation that raises ethical concernsM Amini-Adle, J-P Arnault, F Aubin, et al.
Pageof 6

Showing results (51-60 of 53) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 53 results.
ESMO Open|November 3, 2023
Long term activity of vemurafenib in cancers with BRAF mutations: the ACSE basket study for advanced cancers other than BRAF<sup>V600</sup>-mutated melanomaJ Y Blay, C Cropet, S Mansard, et al.
The British Journal of Dermatology|November 1, 2020
Epidemiological changes in cutaneous lymphomas: an analysis of 8593 patients from the French Cutaneous Lymphoma RegistryG Dobos, A de Masson, C Ram-Wolff, et al.
Annales De Dermatologie Et De Venereologie|February 7, 2024
The combination of ipilimumab and nivolumab is still not reimbursed for BRAF-mutated melanoma patients in France: An unacceptable medical situation that raises ethical concernsM Amini-Adle, J-P Arnault, F Aubin, et al.
Pageof 6